Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 11/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540444 | 1.00 | DRD4 (0.42) | DRD4CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL13341865 | 0.86 | KMT2A (0.42) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL14404437 | 0.83 | CHRM2 (0.37) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL3535193 | 0.81 | CHRM2 (0.41) | DRD4CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL3535190 | 0.81 | CHRM2 (0.41) | DRD4CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL3536643 | 0.78 | CHRM2 (0.40) | DRD4CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL3536639 | 0.78 | CHRM2 (0.40) | DRD4CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL3538507 | 0.77 | MAPT (0.47) | DRD4CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL3538510 | 0.77 | MAPT (0.47) | DRD4CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL3543853 | 0.77 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713978-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-05-11 | — | — | US | disclosed |
| US-7713978-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-05-11 | — | — | US | disclosed |
| US-7713978-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-05-11 | — | — | US | disclosed |
| EP-2013178-A1 | PIPERAZINE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUE (GHS) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20070238737-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| WO-2007113202-A1 | PIPERAZINE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUE (GHS) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113202-A1 | PIPERAZINE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUE (GHS) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| US-20070238737-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-20070238737-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238737-A1 | NOVEL COMPOUNDS | FABP2, VIP, SLC10A2 | DRD4 3501/4885CHRM2 699/4885CHRM1 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.